Metrics as of 10/15/2026, 10:11 AM (Berlin time), refresh in progress.
BioXcel Therapeutics Stock
BioXcel Therapeutics, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Vimal D. Mehta
- Employees
- 29
- Market cap
- $2 M
- IPO
- 08/03/2018
BioXcel Therapeutics, Inc. is a biopharmaceutical firm that has reached the commercial phase, distinguishing itself by leveraging artificial intelligence to advance the creation of transformative therapies in the fields of neuroscience and immuno-oncology. Their distinctive methodology, termed 'drug re-innovation,'…
BioXcel Therapeutics stock: price history
1D
-9.0%
1W
+27.5%
1M
-67.2%
6M
-96.2%
YTD
-97.2%
1Y
-98.2%
2Y
-99.5%
5Y
-100.0%
10Y
–
Next earnings date
Next earnings date
11/11/2026 (in 25 days)
Volatility around earnings
~17% stronger price swings than usual
Ask the agents about BioXcel Therapeutics
Analyst assessment of BioXcel Therapeutics
PRICE TARGET LOW
US$1.00
CONSENSUS
US$12.00
MEDIAN
US$10.00
PRICE TARGET HIGH
US$25.00
0
STRONG BUY
8
BUY
6
HOLD
1
SELL
0
STRONG SELL
15
TOTAL · Buy
As of: 02/04/2026
BioXcel Therapeutics stock metrics
P/E
-0.01
P/B
-0.01
EV/EBITDA
-1.76
RETURN ON EQUITY
12.7%
NET MARGIN
-8,084.1%
DEBT/EQUITY
-0.9
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
97.8%
FLOAT SHARES
30,204,406
AVG. DAILY VOLUME (30D)
11,949,353
Insider transactions (SEC)
Mehta Vimal
Yocca Frank
Steinhart Richard I
Rodriguez Javier
Mehta Vimal
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about BioXcel Therapeutics stock
What does BioXcel Therapeutics do?
BioXcel Therapeutics, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Vimal D. Mehta, the company employs around 29 people.
The IPO was on 08/03/2018; the stock trades on NASDAQ under the ticker BTAI.
What do analysts say about BioXcel Therapeutics stock?
15 analysts rate the stock, the consensus is Buy (as of 02/04/2026).
The average price target is US$12.00, ranging from US$1.00 to US$25.00, with a median of US$10.00.
This is an external assessment, not a statement by Market Jury.
When does BioXcel Therapeutics report next?
The next earnings date is 11/11/2026.
Around past earnings, price swings were roughly 17% stronger than usual.
Does BioXcel Therapeutics pay a dividend?
No, BioXcel Therapeutics currently does not pay a dividend.
Which stocks are comparable to BioXcel Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get BioXcel Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess BioXcel Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.